Search Results - "Errico JM"

Determinants of natural killer cell-mediated antibody dependent cellular cytotoxicity in SARS-CoV-2 antibodies.

Authors: Depierreux, Delphine M. Ruiz, Felicitas Lilly, Michelle et al.

Source: PLoS Pathogens. 3/12/2026, Vol. 22 Issue 3, p1-15. 15p.

Potent efficacy of an NA-targeting antibody against a broad spectrum of H5N1 influenza viruses.

Authors: Moriyama S di Iulio J Zatta F et al.

Source: Nature communications [Nat Commun] 2026 Mar 02; Vol. 17 (1). Date of Electronic Publication: 2026 Mar 02.

Publication Type: Journal Article

Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

Zika virus-specific and orthoflavivirus-cross-reactive IgGs correlate with Zika virus seroneutralization depending on prior dengue virus infection.

Authors: Marquine, Solène Briolant, Sébastien Claverie, Damien et al.

Source: PLoS Neglected Tropical Diseases. 7/9/2025, Vol. 19 Issue 7, p1-15. 15p.

Engineered monoclonal antibody tobevibart enhances HBsAg capture by Fc receptor-positive cells and activates HBV-specific T cells.

Authors: Vincenzetti L Wong R Marzi R et al.

Source: Journal of hepatology [J Hepatol] 2026 Jan; Vol. 84 (1), pp. 62-73. Date of Electronic Publication: 2025 Aug 27.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8503886 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0641 (Electronic) Linking ISSN: 01688278 NLM ISO Abbreviation: J Hepatol Subsets: MEDLINE

A trimer ancestral spike-based mRNA vaccine confers cross-generational protection against SADS-CoV.

Authors: Zhang, Teng Yao, Jiale Guo, Xinchun et al.

Source: Journal of Nanobiotechnology. 11/4/2025, Vol. 23 Issue 1, p1-14. 14p.

This result is not displayed to guests.
Login for full access.

Aptamer-engaged nanotherapeutics against SARS-CoV-2.

Authors: Zhang, Jing Wang, Dan Kwok, Chiu et al.

Source: Discover Nano; 4/27/2025, Vol. 20 Issue 1, p1-22, 22p

Genomic evidence links human dengue cases with undetermined serotypes to sylvatic lineages.

Authors: Suppiah, Jeyanthi Zulkifli, Murni Maya Sari Adiee, Amir Hussin et al.

Source: Tropical Medicine & Health. 8/25/2025, Vol. 53 Issue 1, p1-10. 10p.

A broadly neutralizing monoclonal antibody overcomes the mutational landscape of emerging SARS-CoV-2 variants of concern.

Authors: Parray, Hilal Ahmad Narayanan, Naveen Garg, Sonal et al.

Source: PLoS Pathogens. 12/12/2022, Vol. 18 Issue 12, p1-20. 20p.

Unveiling protection: a meta-analysis of tixagevimab-cilgavimab prophylaxis in 28,950 transplant recipients and immunocompromised patients against COVID-19.

Authors: Moawad, Mostafa Hossam El Din Abbas, Abdallah Sabet, Haneen et al.

Source: Virology Journal. 6/2/2025, Vol. 22 Issue 1, p1-17. 17p.

Delineating the functional activity of antibodies with cross-reactivity to SARS-CoV-2, SARS-CoV-1 and related sarbecoviruses.

Authors: Ruiz, Felicitas Foreman, William B. Lilly, Michelle et al.

Source: PLoS Pathogens. 10/28/2024, Vol. 20 Issue 10, p1-32. 32p.

The S2 subunit of spike encodes diverse targets for functional antibody responses to SARS-CoV-2.

Authors: Guenthoer, Jamie Garrett, Meghan E. Lilly, Michelle et al.

Source: PLoS Pathogens. 8/2/2024, Vol. 20 Issue 8, p1-34. 34p.

Single B cell transcriptomics identifies multiple isotypes of broadly neutralizing antibodies against flaviviruses.

Authors: Lubow, Jay Levoir, Lisa M. Ralph, Duncan K. et al.

Source: PLoS Pathogens. 10/9/2023, Vol. 19 Issue 10, p1-36. 36p.

Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical Trial.

Authors: Shapiro, Adrienne E Sarkis, Elias Acloque, Jude et al.

Source: Open Forum Infectious Diseases. Aug2023, Vol. 10 Issue 8, p1-9. 9p.

Mapping the Evolutionary Space of SARS-CoV-2 Variants to Anticipate Emergence of Subvariants Resistant to COVID-19 Therapeutics.

Authors: Rojas Chávez, Roberth Anthony Fili, Mohammad Han, Changze et al.

Source: PLoS Computational Biology. 6/10/2024, Vol. 20 Issue 6, p1-33. 33p.

Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England.

Authors: Patel, Vishal Levick, Bethany Boult, Stephen et al.

Source: BMC Infectious Diseases. 4/22/2024, Vol. 24 Issue 1, p1-8. 8p.

A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants.

Authors: Lee, I-Jung Sun, Cheng-Pu Wu, Ping-Yi et al.

Source: Journal of Biomedical Science. 7/7/2022, Vol. 29 Issue 1, p1-13. 13p.

High-throughput saturation mutagenesis generates a high-affinity antibody against SARS-CoV-2 variants using protein surface display assay on a human cell.

Authors: Yang, Ye Liu, Shuo Luo, Yufeng et al.

Source: PLoS Pathogens. 2/1/2023, Vol. 18 Issue 2, p1-19. 19p.

Antiviral activity of an ACE2-Fc fusion protein against SARS-CoV-2 and its variants.

Authors: Bermúdez-Abreut, Ernesto Fundora-Barrios, Talia Hernández Fernández, Diana Rosa et al.

Source: PLoS ONE. 1/3/2025, Vol. 20 Issue 1, p1-17. 17p.

Effects of N-glycan modifications on spike expression, virus infectivity, and neutralization sensitivity in ancestral compared to Omicron SARS-CoV-2 variants.

Authors: Lusvarghi, Sabrina Stauft, Charles B. Vassell, Russell et al.

Source: PLoS Pathogens. 11/9/2023, Vol. 19 Issue 11, p1-22. 22p.